Adrenal Suppression and Exogenous Cushing Syndrome After Inhaled and Topical Corticosteroids – Two Clinical Cases and Review of the Subject

Gheorghe Serpoi¹, Constantin Cucu²,³

Abstract

The undesirable endocrine effects associated with pharmacological therapy with corticosteroids administered orally or parenterally are well-known in medical practice. However, the degree of vigilance is lower when compartmental corticosteroids are used, and it is a widely held assumption that local glucocorticoids rarely produce adrenal insufficiency or exogenous Cushing syndrome. The two cases that we present here demonstrate the appearance of major adrenal suppression and Cushing exogenous syndrome after inadequate use of topical corticosteroids and, the combination of inhaled corticosteroids with nasal glucocorticoids, respectively. The following mini-review shows, from the endocrinologist point of view, the main aspects to be considered by practitioners who recommend local glucocorticoid treatments – i.e. inhaled, topical (cutaneous, oral, nasal, ophthalmic) or intraarticular – to prevent the occurrence of major endocrine syndromes that are met after corticosteroid therapy, tertiary adrenal insufficiency and exogenous Cushing syndrome.

Keywords: corticosteroid administration; adrenal suppression; exogenous Cushing

Case Report

Corresponding author:
Gheorghe Serpoi, Clinical Department of Endocrinology, CF2 Hospital, 63-65 Marasti Avenue, Bucharest, Romania.
E-mail: gserpoi@gmail.com

¹ Department of Endocrinology, CF2 Clinical Hospital Bucharest, Romania
² „Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
³ „C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
INTRODUCTION

Corticosteroid (CS) therapy is used by 1% of world population, especially for non-endocrinological indications. Compartmental administration of CS (i.e. topical, inhaled or intraarticular) was developed to prevent undesired effects. Still even these therapies could generate major endocrine syndromes, as our two cases tend to illustrate – Table 1 and Table 2.

Table 1. Case no. 1 description

| Hormonal testing | May 2016* | August 2016* | August 2017* | Feb 2018* |
|------------------|-----------|-------------|-------------|-----------|
| Cortisol range: 101-535 nmol/L | 4.83 nmol/L (0.17 ug/dl) | 27.59 nmol/L (1.0 ug/dl) | 19.31 nmol/L (0.7 ug/dl) | 68.97 nmol/L (2.5 ug/dl) |
| ACTH range: 5-46 pg/ml | 2.43 pg/ml | 7.47 pg/ml | 4.5 pg/ml | 8.65 pg/ml |

* Profound suppression of HPA axis. Clobetasol was discontinued and patient received non-glucocorticosteroid topical treatment. Glucocorticoid replacement therapy begun.

Severe exogenous Cushing syndrome with the following:
- **Severe osteoporosis**, with crushes of the thoracolumbar vertebrae; MRI demonstrated:
  - (1) Grade 3 fracture with compression of the T12 vertebral body, resulting in compression of the vertebral canal and contact with the spinal cord; (2) Grade 2 fractures with anterior and superior compression at L1 and L3; (3) Grade 2 fractures with anterior compression at T5, T7 and T8; diffuse demineralization (according to Genant method of assessment).
- **Diabetes mellitus and obesity.**
- **Sub-capsular cataract** – treated with bilateral crystalline replacement.

Table 2. Case no. 2 description

| Hormonal testing (blood, 8AM) | August 2013a | 1st visit - Aug 2015b | 2nd visit - Feb 2017c | 3rd visit - May 2017d | 4th visit - Nov 2017e |
|-------------------------------|--------------|----------------------|----------------------|----------------------|----------------------|
| Cortisol range: 101-535 nmol/L | 25.1 nmol/L (0.9 ug/dl) | 287 nmol/L (10.4 ug/dl) | 26.9 nmol/L (0.97 ug/dl) | 70.7 nmol/L (2.56 ug/dl) | 180.8 nmol/L (6.55 ug/dL) |
| ACTH range: 5-46 pg/ml | 5.48 pg/ml | 31.6 pg/ml | <1 pg/ml | 9.98 pg/ml | 28.7 pg/ml |
| DHEA-S range: 49-362 pg/ml | - | 27.5 pg/ml | 20.3 pg/ml | - | 26.4 pg/dL |
| Androstenedione range: 0.64-2.97 ng/ml | - | 0.62 ng/ml | - | - | - |
| Renin range: 4.4-46.1 pg/ml | - | 14 uU/ml | - | - | - |

SIDEBAR. The possibility of exogenous Cushing syndrome after treatments with topical corticosteroids was also emphasized in earlier syntheses. In an article from 2012 are depicted 5 cases of Cushing syndrome occurring after clobetasol-propionate topical treatments. The patient presented by us stands out by the severity of clobetasol-induced osteoporosis, suggesting a persistent and long-lasting exposure at high doses.

ACTH = corticotropin, HPA = hypothalamic-pituitary-adrenal.
Two years before referral – tests suggestive of adrenal suppression preceding the assumed adrenal crisis during the sepsis.

One month after presumed adrenal crisis. Tests indicate a normal cortisol response (i.e. >20 µg/dL 24h after Synacthen), but a low level of adrenal androgens (AA). Low AA suggests relative AI². Dissociation between GC and AA might be generated by sepsis³.

In February 2017 clinical exam revealed findings suggesting of recurrent exogenous Cushing syndrome: muscular wasting, weight gain with fat redistribution, facial plethora, persistently high BP values, and high self-monitoring glycaemia (170-250 mg/dL). We found out about the use of nasal betamethasone with an intensification of self-administration suggesting overtreatment in the last 6 months. Betamethasone stopped.

HPA function was still subnormal, with low cortisol and inadequately normal ACTH - tertiary hypoadrenalism. GC replacement therapy begun - prednisone 5 mg/day.

In November 2017, 9 months after nasal betamethasone was stopped, HPA axis function was still impaired; the control of diabetes was improved - Glycaemia= 105 mg/dL, HbA1c = 6.1%. The GC replacement therapy was gradually suspended, maintaining CS supplementation in stress and re-test HPA-axis after 3 months.

SIDEBAR. A case of Cushing syndrome following ICS, as we presented here, was reported in 2013, where concomitant use of intranasal GC played an important role, too⁴.

GC = glucocorticoid; ICS - inhaled corticosteroid; ACTH = corticotropin; DHEA-S = dehydroepiandrosterone-sulfate; HPA = hypothalamic-pituitary-adrenal; HbA1c = Glycated hemoglobin.

LOCAL (COMPARTMENTAL) GLUCOCORTICOID ADMINISTRATION – ENDOCRINOLOGIST MINI-REVIEW

According to the pharmaceutical route of administration glucocorticoid (GC) therapy can be divided in: (a) systemic: oral, intravenous, intramuscular, and subcutaneous; (b) local or compartmental: topi (cutaneous, nasal, ophthalmic); inhaled; intraarticular. The therapeutic index for GC depends on the systemic absorption of the drug, the metabolism (renal and/or hepatic clearance) and the degree of plasma protein binding.

Topical GC are used for a large spectrum of dermatological conditions and show a great variability in terms of bioavailability and pharmacokinetics (e.g. the fluorinated compounds, dexamethasone, triamcinolone, betamethasone, and beclomethasone are better absorbed through skin than the unfluorinated agents like hydrocortisone). Topical GC can be classified according to their potency and the capacity to inhibit HPA axis - Table 3 [based on World Health Organization (WHO) classification]. As a rule, higher dermal potency will result in higher degree of HPA axis suppression and risk for adrenal insufficiency (AI). Super-active agents such as clobetasol ointment 0.05% can produce HPA suppression at doses as low as 2g/day and can result in Cushing syndrome at doses larger than 50 g/week (our patient in case no. 1 using 200 g/week). Pharmacological estimation showed that daily topical use of 20 mg clobetasol (= 40 g ointment clobetasol-propionate 0.05%) have the same systemic effect as the daily oral dose of 60 mg prednisone. Accordingly, therapy with clobetasol should not exceed 50 g/week, no longer than 2 weeks on a row.

Children showed a greater sensibility with HPA suppression demonstrated at doses of 14 g/week clobetasol-propionate or 49 g/week betamethasone-dipropionate⁵. There are reported an increasingly number of cases with HPA axis severely suppressed. In our patient (case no. 1), AI persisted even after 20 months since clobetasol suspension.

Inhaled corticosteroids (ICS), are pivotal to achieve asthma control in both children and adults. In Ta-
6 months and if were associated with hypoglycemia, mental impairment, fatigability, anorexia, Cushingoid appearance or impaired linear growth.

ENDOCRINE EFFECTS OF COMPARTMENTAL GC ADMINISTRATION

The undesired side effects after compartmental GC administration could be local, specific to type of therapy and systemic, common to all types. The endocrine systemic effects are: (1) HPA axis suppression; (2) exogenous Cushing syndrome.

(1) HPA axis suppression and adrenal insufficiency

GC therapy is the most common cause of adrenal insufficiency (AI). GC administration decrease hypothalamic-corticobulin (CRH), as well as pituitary adreno-corticotropic hormone (ACTH) production and induce adrenocortical cells functional inhibition and atrophy. GC use in a dose larger than the equivalent of 20 mg prednisone/day for more than 3 weeks can induce HPA-axis suppression. When are taken at the bed-time even doses of ≥5 mg prednisone/day can induce suppression12. Adrenal suppression was documented both after oral GC and after ICS13. In a study of HPA function after systemic GC use in 3166 patients, the median prevalence of AI was 37% and the recovery of the normal function occurred in 58.8% patients 1-2 years after systemic GC withdrawal14. In a recent study with 404 patients taking oral, topical, intranasal or inhaled GC therapy, 33.2% had a subnormal short Synacthen stimulation test (SST) response15.

In a meta-analysis conducted on 3753 subjects exposed to ICS are sorted according with potency and HPA suppression. One ICS with higher potency needs lower inhaled daily dose for equivalent efficacy.

The schematic pharmacokinetic of ICS: (a) - 60-90% of the inhaled drug remains in pharynx and it is swallowed; from gut, it is absorbed and inactivated in liver at the first-pass by enzymes linked with CYP3A2. Inhibitors for CYP3A cytochrome increase the GC levels and amplifies systemic effects (moderate inhibitors, e.g. diltiazem; tibolone; dronedarone; amiodarone; mifepristone; erythromycin; fluconazole; grapefruit juice, and strong inhibitors, e.g., ceritinib; indinavir; clarithromycin; itraconazole; ketoconazole). Ciclesonide, fluticasone and mometasone are virtually completely metabolized, while 11% budesonide and 20-40% beclomethasone escapes the first-pass and reach the systemic circulation. Therefore, it is better to select one ICS with greater hepatic clearance. (b) - 10-40% of the inhaled drug reach the respiratory system and then delivered into circulation (e.g. 20% of inhaled fluticasone).

In terms of prednisolone equivalency, adrenal suppression with a large dose of budesonide (1000 ug per day) was estimated to be as high as with 8.7 mg of prednisolone8. Important dose-effect relationship between ICS and urinary cortisol suppression was documented with beclomethasone (8.4% per 100 μg; p =0.029), followed by fluticasone (3.2% per 100 μg; p <0.001), and budesonide (3.1% per 100 μg; p = 0.001); no significant suppression was associated with ciclesonide9. Pharmacological properties of ciclesonide made it the safest ICS [i.e. - 160-600 ug/day ciclesonide didn’t affect cortisol level]10. The highest risk for adrenal suppression is encountered in children, especially when ICS was fluticasone11, if the ICS were used for more than

| ICS                 | Asthma potency | HPA suppression | Daily dose [ug] suppressing cortisol 20% | Equivalent dose (ug/day) |
|---------------------|----------------|-----------------|------------------------------------------|--------------------------|
| Fluticasone - proprionate | ++++           | ++++            | 900                                      | 100-250                  |
|                     |                |                 |                                          | 250-500                  |
|                     |                |                 |                                          | >500                     |
| Mometasone - furoate | +++            | ++++            | 660                                      | 200                      |
|                     |                |                 |                                          | 200-400                  |
|                     |                |                 |                                          | >400                     |
| Beclomethasone - dipropionate | ++          | +++            | 500                                      | 100-200                  |
|                     |                |                 |                                          | 200-400                  |
|                     |                |                 |                                          | >400                     |
| Budesonide          | +              | ++              | 600                                      | 200-400                  |
|                     |                |                 |                                          | 400-800                  |
|                     |                |                 |                                          | >800                     |
| Ciclesonide         | +++            | -               | 1200                                     | 80-160                   |
|                     |                |                 |                                          | 160-320                  |
|                     |                |                 |                                          | >320                     |

* NOTE: Therapeutic index is defined as the dose that produces 20% cortisol suppression divided by the therapeutic dose – the higher is this index the lower is the risk that ICS produces systemic effects.

ICS = inhaled corticosteroid; HPA = hypothalamic-pituitary-adrenal axis.
systemic or local GC, the percentages of tertiary AI were: 48.3% - after systemic GC; 6.8% - after ICS; 4.7% - after topical corticosteroids; 4.2% - after intranasal GC; 52.2% - after intraarticular GC. The combined GC therapy (i.e. ICS and intranasal GC) resulted in a higher risk of HPA suppression (e.g. an 19% excess). In a recent article, 61% of patients with adrenal suppression after systemic GC had normal SST after 2 years. In this study, age, gender, body mass index, indications for GC use, and basal corticotropin levels were not predictive of HPA axis recovery; one useful finding was that early morning cortisol of 8.8μg/dL predicted a positive SST response.

Specific factors for prediction of HPA suppression after local GC are in Table 5.

The basic principle for the GC withdrawal is to avoid sudden discontinuation. Instead, the daily dose gradually decreases with 2.5 mg prednisone/day every 3-4 days, until are reached physiological doses (= equivalent of 5-7.5 mg prednisone/day). Estimations are based on physiological cortisol production 5.7-7.4 mg/m²/day, corresponding to a daily dose of 10-15 mg hydrocortisone/m²/day, orally or 6-8 mg/m²/day, intravenous, lower than previously thought. After these doses are reached, taper slower, 1 mg prednisone every 2-4 weeks until cessation OR testing with SST and stop the GC whenever the test is normal. Proposed algorithm for HPA assessing for practitioners using GC therapy – see Table 6.

Adrenal crisis is a medical emergency. Adrenal crisis in tertiary AI occur after abrupt discontinuation of GC. The frequency of adrenal crisis is higher in tertiary AI, i.e. 15.1 cases in 100 patients/year, than in primary AI, 5.2 cases, or secondary AI, 3.6 cases in 100 patients/year. In Table 7 are presented the updated criteria for diagnosis of adrenal crisis and basic treatment measures.

(2) Exogenous Cushing syndrome

Exogenous Cushing syndrome is the most common form of Cushing syndrome. The main features and resemblances with endogenous Cushing syndrome are listed in Table 8. In children, first significant undesired effect associated with GC use is diminished linear growth, encountered even with short-term ICS (i.e. 7 days) if high-doses are used.

Glucocorticoid-induced osteoporosis (GIO) is one of most important feature of exogenous Cushing syndrome and the most frequent form of iatrogenic osteoporosis. GC effects on bone result in 2 phases: first
Step I – Risk estimation

Who to screen?

- Cushingoid appearance, OR
- suspected AI: weakness, anorexia, nausea, diarrhea, abdominal pain, morning headaches, myalgia, arthralgia, hypoglycemia, hypotension, OR
- large ICS doses (i.e. fluticasone or mometasone >400 µg/day; budesonide or beclomethasone >800 µg/day) – for >3 weeks in last 3 months
- large topical corticosteroids doses– clobetasol 0.05% >2 g/day or treatment over 2 weeks with >100 g clobetasol /week, OR
- association with oral GC >2 weeks continuously or >3 weeks in last 6 months, OR
- association with CYP450 3A inhibitors, OR
- yearly for any patient using large doses of compartmental GC

How to screen?

- Morning 8-9 AM serum cortisol* - A baseline cortisol result below 100 nmol/l is considered highly indicative of adrenal insufficiency
- Free urinary cortisol - [normal range in children = 5.5-74 nmol/L (2-26 ug/L); in adults = 14-152 nmol/L (5-55 ug/L)]

Step II – Normal functioning hypothalamic-pituitary-adrenal (HPA) axis

Cortisol > 348 nmol/L (12.6 ug/dL)

→ rules out significant suppression of HPA axis; no need for oral substitution therapy or GC supplementation before major surgery.

If the manifestation of adrenal deficit is persistent → perform SST

Step III – Equivocal functioning HPA axis

Cortisol = 35-348 nmol/L (1.26-12.6 ug/dL)

→ Diagnose adrenal insufficiency - no need to perform SST
- start substitution therapy or GC; supplements before major surgery;
- reduce doses of compartmental GC;
- repeat cortisol testing in 3 months.

Step IV - Suppressed HPA axis

Cortisol <35 nmol/L (<1.26 ug/dL)

→ Diagnose adrenal insufficiency - no need to perform SST
- start substitution therapy or GC; supplements before major surgery;
- reduce doses of compartmental GC;
- repeat cortisol testing in 3 months.

Note! In patients treated with local GC even excessive amounts, resulting in Cushingoid traits might not result in sufficient serum concentration in stress situations. That’s why local GC withdrawal needs the concomitant use of oral GC with replacement dose and GC supplementation in stressful events.

* NOTE. Synacthen is not available in Romania, and insulin-induced hypoglycemia test (ITT), the gold standard for assessing the HPA axis, is cumbersome to use outside endocrinological units. This is the reason why we searched validated basal tests for rapid detection and/or referral of adrenal suppression. HPA = hypothalamic-pituitary-adrenal axis; GC = glucocorticoids; AI = adrenal insufficiency; ICS = inhaled corticosteroids; SST = short Synacthen stimulation test.

Table 6. Algorithm for HPA-suppression during local GC administration

Table 7. Definitions, severity and treatment of adrenal crisis

| Definition | A) Major impairment of general health with at least two of the following: |
|------------|--------------------------------------------------------------------------|
|            | 1. Hypotension (systolic blood pressure <100 mmHg)                      |
|            | 2. Nausea or vomiting                                                   |
|            | 3. Severe fatigue                                                       |
|            | 4. Fever                                                                |
|            | 5. Somnolence                                                           |
|            | 6. Hyponatraemia (≤132 mmol/l) or hyperkalaemia                         |
|            | 7. Hypoglycaemia                                                        |

| B) Prompt clinical improvement after parenteral hydrocortisone |
|---------------------------------------------------------------|

| Severity | Grade 1 – outpatient care only                                      |
|----------|--------------------------------------------------------------------|
|          | Grade 2 – hospital care (general ward), no need for intensive care|
|          | Grade 3 – admission to intensive care unit                         |
|          | Grade 4 – death from adrenal crisis (with or without GC administration) |

| Treatment confirmed or suspected adrenal crisis [treatment is started before biochemical confirmation] |
|------------------------------------------------------------------------------------------------------|
| → Establishing an intravenous route                                                                 |
| → Sampling the blood for glycaemia, Na, K, hemoleucogram, cortisol                                  |
| → Hydrocortisone: 100 mg bolus given immediately followed by 200 mg/ day as continuous infusion or frequent i.v./i.m. boluses (50 mg) every 6 h |
| → Intravenous substitution of fluids: 1000 ml of 0.9% sodium chloride during the first 60 min + glucose 5% [if hypoglycaemia]; further fluid administration (0.9% sodium chloride) guided by individual needs as assessed clinically or by central venous pressure and avoiding overload. The quantity infused depends on evolution of blood-pressure, heart rate, diuresis, ionogram, central venous pressure and pulmonary auscultation |
| → Depending on the severity of the crisis and on the intercurrent illness [e.g. low-dose heparin; antibiotic treatment] |

15,17,19
21
Table 8. Cushing syndrome – comparation between endogenous and exogenous types

| Exclusive in exogenous Cushing | More frequent in endogenous Cushing |
|-------------------------------|-----------------------------------|
| Intracranial hypertension     | Arterial hypertension             |
| Glaucoma, cataract            | Acne and hirsutism                |
| Aseptic bone necrosis         | Menstrual abnormalities           |
| Pancreatitis                  | Striae and ecchymosis             |
| Panniculitis                  | Plethoric facies                  |

In both endogenous and exogenous Cushing

Central obesity and fat redistribution. Peripheral myopathy and cardiomyopathy

Osteoporosis. Atherosclerosis and thrombosis. Peptic ulceration and digestive bleeding

Glucose intolerance and diabetes mellitus. Natrium retention and potassium excretion

Psychological changes – lability, insomnia, psychosis, cerebral atrophy

Delayed healing. Immunosuppression and lymphopenia; undercurrent infections

Diminution of height growth in children

Table 9. Treatment of GIO in adults\textsuperscript{27,28}

| FRAX GC-adjusted* | ATTITUDE |
|-------------------|----------|
| CATEGORY - Adults \( \geq 40 \) years of age, with GC therapy for \( \geq 3 \) months |
| Low fracture risk - FRAX 10-year risk of major osteoporotic fracture* <10% and risk of hip fracture \( \leq 1\% \) | Prefer optimize calcium intake (0.8-1 g/day) and vitamin D intake (600-800 IU/day) and lifestyle modifications (balanced diet, smoking cessation, regular weight-bearing or resistance training exercise, limiting alcohol to 1-2 alcoholic beverages/day) over treatment with bisphosphonates, teriparatide, denosumab, raloxifene. |
| Moderate fracture risk - FRAX 10-year risk of major osteoporotic fracture 10-19% or risk of hip fracture 1-3% | ORAL BISPHOSPHONATE. Based on cost-effectiveness criteria alendronate and risedronate are preferred. Prefer an oral bis-phosphonate over IV bisphosphonates, teriparatide, denosumab. If oral bisphosphonates are not appropriate, in order: (1) intravenous (IV) bisphosphonates – acid zoledronic; (2) teriparatide*; (3) denosumab (4) raloxifene. |
| High fracture risk: Very high-dose GC*** OR FRAX risk of major osteoporotic fracture \( \geq 20\% \) or risk of hip fracture \( \geq 3\% \) OR prior osteoporotic fracture OR hip/spine bone mineral density (BMD) T score \( \leq -2.5 \) in men age \( \geq 50 \) years or post-menopausal women. | ORAL BISPHOSPHONATE. Treat with an oral bisphosphonate over IV bisphosphonates, teriparatide, denosumab, or raloxifene. If oral bisphosphonates are not appropriate, in order: (1) IV bisphosphonates [higher risk profile for IV]; (2) Teriparatide [cost and burden of injections]; (3) Denosumab [lack of safety data in people treated with immunosuppressive agents]; (4) Raloxifene, for postmenopausal women [lack of adequate data on benefits (impact on risk of vertebral and hip fractures in GC users) and potential harms (clotting risks, mortality)]. |

SPECIAL CASES IN THIS CATEGORY

Adults age \( \geq 40 \) years continuing GC treatment who have had a fracture that occurred after \( \geq 18 \) months of treatment with an oral bisphosphonate or who have had a significant loss of BMD (\( \geq 10\%/year \)) → Treat with another class of OP medication (teriparatide or denosumab; or, consider IV bisphosphonate).

Adults age \( \geq 40 \) years who have completed 5 years of oral bisphosphonate treatment and who continue GC treatment and are assessed to be at moderate-to-high risk of fracture → Continue active treatment, with an oral bisphosphonate beyond 5 years or switch to IV bisphosphonate.

| CATEGORY - Adults \( <40 \) years of age, with GC therapy for \( \geq 3 \) months |
| Low risk = None of above risk factors other than GC | Optimize calcium and vitamin D intake and lifestyle modifications over treatment with bisphosphonates, teriparatide, or denosumab. |
| Moderate fracture risk = Hip or spine BMD Z score < -3 OR rapid bone loss (\( \geq 10\% \) at the hip or spine over 1 year) + continuing GC at \( \geq 7.5 \) mg prednisone/day for \( \geq 6 \) months | TREAT WITH AN ORAL BISPHOSPHONATE over calcium and vitamin D alone. Oral bisphosphonate over intravenous (IV) bisphosphonates, teriparatide, or denosumab [oral bisphosphonates preferred for safety, cost, and because of lack of evidence of superior antifracture benefits from other medications]. |
| High fracture risk = Prior osteoporotic fracture(s) | If oral bisphosphonates are not appropriate, in order of preference: (1) IV bisphosphonates; (2) Teriparatide; (3) Denosumab. Estimate the need for sexual hormones therapy in premenopausal women with amenorrhea and in men with hypogonadism. |

\textsuperscript{*} FRAX-GC = FRAX-glucocorticoid adjusted risk – increase the risk generated with FRAX – by 1.15 for major osteoporotic fracture and 1.2 for hip fracture if GC treatment is equivalent \( >7.5 \) mg prednisone/day.

\textsuperscript{**} High-dose GC treatment = prednisone \( \geq 30 \) mg/day and a cumulative dose of \( \geq 6 \) g in the past year.

\textsuperscript{***} Very high-dose GC treatment = prednisone \( >200 \) mg/day in exogenous Cushing or \( >100 \) mg/day for \( >40 \) years in endogenous Cushing.

\textsuperscript{****} Very high-dose GC treatment = prednisone \( >30 \) mg/day for \( >40 \) years or post-menopausal women.

Modern Medicine | 2018, Vol. 25, No. 2 | 101
rapid bone mass, 12% in the first 3-12 months followed by a phase of slower bone mass loss, of 2-15% every 12 months. GIO can occur not only after systemic CS, but with ICS23 and topical GC24. One short guide for prevention and treatment of GIO is presented Table 9.

CONCLUSION

It is estimated that approximately 6% of hospitalized patients have GC-induced tertiary AI25. In this article, we intended to draw attention to the endocrine effects generated by compartmental GC treatments. GC preparations with the so-called local effects (e.g. topical, inhaled, intra-articular) have been shown to exert systemic effects that can not be neglected, the most important for endocrinologists being exogenous Cushing syndrome and glucocorticoid-induced AI. One meta-analysis showed evidence of AI following low doses and short durations of GC (<5 mg prednisolone equivalent dose/day, <4 weeks of exposure, cumulative dose <0.5 g, and following tapered withdrawal)26. There is no clinical guidance for AI occurring after systemic CS and even lesser agreements for AI induced by local GC. This data must lead the practitioners using topical, inhaled, or intra-articular GC to an increased alertness level toward the possibility that even compartmental administration could cause significant systemic endocrine effects.

Compliance with ethics requirements:
The authors declare no conflict of interest regarding this article.
The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law. Informed consent was obtained from all the patients included in the study.

References

1. Decani S, et al. Iatrogenic Cushing’s syndrome and topical steroid therapy. Case series and review of the literature. J. Derma tol. Treat. 2014; 25, 495–500.
2. Fischli S, et al. Dehydroepiandrosterone Sulfate in the Assessment of the Hypothalamic–Pituitary–Adrenal Axis. J Clin Endoc rino1 Metab 2008; 93: 539–542.
3. Beshuizen A, et al. Decreased levels of dehydroepiandrosterone sulphate in severe critical illness: a sign of exhausted adrenal reserve? Critical Care 2002; 6:434.
4. Dow A, Yu R, Carmichael J. Too little or too much corticosteroids? Coexisting adrenal insufficiency and Cushing’s syndrome from chronic, intermittent use of intranasal betamethasone. Endocrinology, Diabetes & Metabolism Case Reports 10 2013, EDM130036.
5. Hengge UR, et al. Adverse effects of topical glucocorticoster oids. J Am Acad Dermatol 2006;54:1–15.
6. National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3); Guidelines for the Diagnosis and Management of Asthma; 2007 & Global Initiative for Asthma (GINA) Management and Prevention; 2014.
7. Daley-Yates PT. Inhaled corticosteroids potency and therapeu tic index. Br J Clin Pharmacol 2015;80:3:372-380.
8. Toogood JH, et al. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989;84:688–700.
9. Kowalski ML, et al. Adrenal suppression by inhaled corticoSteroids in patients with asthma: A systematic review and quantitative analysis. Allergy Asthma Proc. 2016, 37, 9–17.
10. Dahl R. Systemic side effects of inhaled corticosteroids in patients with asthma. Respiratory Medicine 2006; 100: 1307–1317
11. Todd GR, et al. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 2002;87:457–61.
12. Guaraldi F, et al. Secondary adrenal insufficiency. Where is it hidden and what does it look like? Front. Horm. Res. 2016, 46, 159–170.
13. Mortimer KJ, et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax. 2006 May;61(5): 405-8.
14. Baek JH, et al. Recovery of Adrenal Function in Patients with Glucocorticoids Induced Secondary Adrenal Insufficiency. Endocrinol Metab 2016; 31:153-160.
15. Woods CP, et al. Adrenal suppression in patients taking inhaled glucocorticoids is highly prevalent and management can be guided by morning cortisol. European Journal of Endocrinology 2015;173: 639–642.
16. Broersen et al. Adrenal Insufficiency in Corticosteroids Use. J Clin Endocrinol Metab 2015; 100: 2171–2180.
17. Leong SH, Shander S, Ratnasigam J. Predicting Recovery of The Hypothalamic–Pituitary–Adrenal Axis After Prolonged Gluco corticoid Use. Endocr Pract. 2018 Jan; 24(1):14-20.
18. Paragioila RM, Corsello SM. Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment. Minerva Endocrinol. 2017.
19. Bondugulapati LN, Rees DA. Recommendations for management of ICS-induced hypothalamic–pituitary–adrenal axis suppression. Clin Endocrinol. 2016; 85(2):165–169.
20. Smans LC, et al. Incidence of adrenal crisis in patients with adrenal insufficiency. Clin. Endocrinol. Oxf. 2016, 84, 17–22.
21. Altollo B. Adrenal Crisis. European Journal of Endocrinology 2015; 172, R115–R124.
22. Jackson DJ, et al. Quintupling Inhaled Glucocorticoids to Prevent Childhood Asthma Exacerbations. N Engl J Med, March 3, 2018, DOI: 10.1056/NEJMoa1710988.
23. Singh S and Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010; 5:189–195.
24. Millard TP, et al. Bone mineral density of patients with chronic plaque psoriasis. Clin Exp Dermatol. 2001;26:446–8.
25. Paragioila RM, et al. Treatment with Synthetic Glucocorticoids and the Hypothalamic-Pituitary-Adrenal Axis. Int. J. Mol. Sci. 2017, 18, 2201.
26. Joseph RM, et al. Systemic glucocorticoid therapy and adrenal insufficiency in adults: A systematic review. Seminars in Arthritis Rheumatism 2016; 46, 133–141.
27. Buckley L, et al. 2017 ACR Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2017 Aug; 69(8):1521–1537.
28. Compton J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2017; 12:43, 1-24.